Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

and we are excited to be moving our clinical program forward. We are very pleased that the MMRC sponsorship has made the rapid initiation of our Phase 2 trials possible and has enabled us to reach out to a larger group of myeloma patients. The thoughtful scientific expertise and collaborative effort of this group have helped speed development of new agents in the field of multiple myeloma," said Lori A. Kunkel, M.D., Chief Medical Officer of Proteolix, Inc.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 Member Institutions: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, Saint Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University. In addition to these trials with Proteolix, the MMRC is supporting six other clinical trials exploring several investigative agents.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas- genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Colo. , Dec. 15, 2014  The Government of ... collaboration of AABB, Global Blood Fund (GBF) and Terumo BCT to ... , as well as provide long-term health system capacity to ... Facts: , The Ghanaian Ebola Readiness and Resilience Initiative ... Ghana,s preparations for the possible arrival of the ...
(Date:12/13/2014)... Research and Markets ( http://www.researchandmarkets.com/research/2r6bmg/drug_injection ... "Drug Injection Devices to 2020" report to ... As new drugs become available ... health conditions, drug developers have increasingly pursued packaging ... and increase the efficiency and reliability with which ...
(Date:12/13/2014)... , Dec. 12, 2014 HudsonAlpha ... the HiSeq X Ten sequencing system manufactured by ... HudsonAlpha to produce and analyze genomic data faster ... from the Institute,s commitment to research programs for ... HiSeq X Ten provides unprecedented capacity, speed and ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... Overactive Bladder Treatment for... -- ARDEE, Ireland, Oct. 18 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Medicine Technology:Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 2Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 3Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 4Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 5Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 6Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 7Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 8Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 9Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 2Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 3Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 4Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 5Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 6Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 7Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 8
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... pilots process visual information more efficiently than less experienced ... landings, a new study shows. Landing is one ... and 36 percent of all airplane crashes and 25 ... landing. Researchers monitored the brain activity of eight ... were at the controls of a flight simulator. As ...
(Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... molecules found in certain plants appears to have a beneficial ... a new study conducted in mice. The study was led ... Medical Center. An article in the Journal of Cellular and ... of the senior authors of the study, is available to ...
... 7 /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) (OTC Bulletin ... of healthcare related disinfectants in China,announced today ... Hi-Tech Company, Ltd., (LiKang Disinfectant) began training,and ... Olympics. The project,is sponsored by and under ...
... to Provide ... for Their Families, CHICAGO, May 7 Mother,s Day is ... gatherings and gifts,and to honor those who give so much to their families ... of those mothers who,live in poverty and need the assistance of programs offered ...
... Emory Winship Cancer Institute, ATLANTA, May 7 ... commitment of $50,000 to the Emory Winship Cancer ... southeast focused on,triple-negative breast cancer research. Dan Amos, ... president, made the personal donation,in honor of the ...
... The Female Health Company,(Amex: FHC ) today ... discuss its operating results for the second quarter of ... 14, 2008. The Company plans to,report its second quarter ... and other interested parties may participate in the,conference call ...
... Highlighted, TAMPA, Fla., May 7 Acute pain ... than 25 million,Americans are said to experience acute pain ... a recent study estimated that 42 percent of U.S.,hospital ... Seven clinical presentations on tapentadol immediate release (IR),tablets for ...
Cached Medicine News:Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 2Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 3Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 4Health News:Catholic Charities Calls for Increased Support of Mothers in Need: 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 3Health News:The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 3Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 4
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: